Deal●
Novartis signs mRNA therapy deal with China's Abogen worth about $7.8 billion
- Abogen will receive $575 million upfront and up to $7.2 billion in milestone payments
- Milestones depend on clinical development, approvals and commercial milestones
- The deal highlights global pharma licensing activity, with limited direct read-through for Indian drugmakers